With Shortage Looming Large, Cipla Offers Generic Tamiflu, Relenza To U.S. Health Department
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Known for supplying low-priced anti-retroviral cocktail therapy to frontline African nations to combat the spread of HIV/AIDS, Cipla - India's largest drug maker by market share - is in discussions with U.S. health agencies to boost production of antiviral oseltamivir, the generic for Roche's Tamiflu for treating the rapidly spreading H1N1 virus